166 related articles for article (PubMed ID: 38001504)
1. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.
Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
Arthritis Res Ther; 2023 Nov; 25(1):226. PubMed ID: 38001504
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of
Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675722
[TBL] [Abstract][Full Text] [Related]
3. Role of
Sainz L; Riera P; Moya P; Bernal S; Casademont J; Díaz-Torné C; Millán AM; Park HS; Lasa A; Corominas H
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145690
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis.
Enevold C; Baslund B; Linde L; Josephsen NL; Tarp U; Lindegaard H; Jacobsen S; Nielsen CH
Pharmacogenet Genomics; 2014 Aug; 24(8):401-5. PubMed ID: 24978393
[TBL] [Abstract][Full Text] [Related]
5. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.
Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Ángel Calleja-Hernández M
Pharmacogenomics J; 2018 Jan; 18(1):167-172. PubMed ID: 27958380
[TBL] [Abstract][Full Text] [Related]
6. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.
Luxembourger C; Ruyssen-Witrand A; Ladhari C; Rittore C; Degboe Y; Maillefert JF; Gaudin P; Marotte H; Wendling D; Jorgensen C; Cantagrel A; Constantin A; Nigon D; Touitou I; Gottenberg JE; Pers YM
Pharmacogenomics J; 2019 Aug; 19(4):368-374. PubMed ID: 30647443
[TBL] [Abstract][Full Text] [Related]
7. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 Receptor (IL6-R) Gene Polymorphisms Underlie Susceptibility to Rheumatoid Arthritis.
Ahmed S; Hussain S; Ammar A; Jahan S; Khaliq S; Kaul H
Clin Lab; 2017 Sep; 63(9):1365-1369. PubMed ID: 28879718
[TBL] [Abstract][Full Text] [Related]
9. Associations between the interleukin-6 rs1800795 G/C and interleukin-6 receptor rs12083537 A/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: A meta-analysis.
Lee YH; Song GG
Int Immunopharmacol; 2022 Nov; 112():109184. PubMed ID: 36058033
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
[TBL] [Abstract][Full Text] [Related]
11. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
12. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
[TBL] [Abstract][Full Text] [Related]
14. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
[TBL] [Abstract][Full Text] [Related]
15. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
[TBL] [Abstract][Full Text] [Related]
16. Genetic Biomarkers as Predictors of Response to Tocilizumab in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Janahiraman S; Too CL; Lee KW; Shahril NS; Leong CO
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886067
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab.
Lin N; Damask A; Boyapati A; Hamilton JD; Hamon S; Ternes N; Nivens MC; Penn J; Lopez A; Reid JG; Overton J; Shuldiner AR; Abecasis G; Baras A; Paulding C
Pharmacogenomics J; 2022 May; 22(3):160-165. PubMed ID: 35149777
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
20. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
